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AN ALTERNATIVELY SPLICED TRANSCRIPT OF ADAMTS4 IN HUMAN
OSTEOARTHRITIS SYNOVIUM
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Purpose: To describe and characterize a newly discovered alternatively
spliced transcript of the ADAMTS4 aggrecanase.
Methods: Human OA synovium was digested and synovial cell cultures
established. RT-PCR analysis was performed using oligonucleotide primers
designed to amplify across the exon 8/9 region of human ADAMTS4. RT-PCR
was performed and PCR products puriﬁed using a QIAquick puriﬁcation kit
(Qiagen) and sequenced using in house facilities.
A pCEP4 (Invitrogen) mammalian expression vector containing ADAMTS4
plus a FLAG epitope was mutated using QuikChange II site directed muta-
genesis kit (Stratagene) to contain the ADAMTS4 splice variant plus a FLAG
epitope. The recombinant proteins were puriﬁed from HEK293 transfected
cells using Anti-FLAG M2 aﬃnity gel (Sigma).
Results: Destruction of articular cartilage is a key feature of osteoarthritis.
Aggrecan degradation is followed by irreversible collagen degradation. The
degradation of aggrecan is mainly mediated by the aggrecanases, mul-
tidomain metalloproteinases belonging to the ADAMTS family, in which
ADAMTS4 (aggrecanase-1) and ADAMTS5 (aggrecanase-2) are the most
studied. Although alternative splicing has previously been described in
other ADAMTS members, we here describe and characterise the ﬁrst known
alternative splice variant of ADAMTS4.
RT-PCR on human OA synovial cells using the above primers resulted
in the ampliﬁcation of two products: normal ADAMTS4 and a smaller
product missing 161 base pairs from the 5’ end of exon 9, the result of
alternative splicing in which exon 8 joins to a cryptic 3’ splice site within
exon 9. The protein produced would lack the spacer domain and have a
different C-terminus lacking homologies with the normal human ADAMTS4
C-terminal spacer domain.
The alternatively spliced transcript of ADAMTS4 has been found in cultured
OA synovial cells and in freshly digested OA synovium, but not in human
brain, cervix or lung, or in normal bovine synovium.
The predicted protein synthesized from this alternatively spliced transcript
of ADAMTS4 would lose functions dependent on its spacer domain, like
substrate and matrix binding, and inhibition through ﬁbronectin. Removal
of the spacer domain from ADAMTS4 increases its ability to cleave aggre-
can, and it may well be that this alternatively spliced transcript produces
a protein that is secreted in an active form, capable of cleaving the
Glu373-Ala374 bond in the interglobular domain of aggrecan.
HEK293 cells transfected with a pCEP4 vector containing the cDNA se-
quence of the splice variant of ADAMTS4 produced the corresponding
protein in both the pro and active form. This protein could be found in the
media, but mostly associated with the cells, as conﬁrmed using antibodies
speciﬁc for the splice variant that were produced using synthetic peptides.
Proteins puriﬁed by immunoprecipitation by Anti-FLAG M2 aﬃnity gel
from transfected and untransfected HEK293 cells were analysed using
the ANASpec SensoLyte 520 Aggrecanase I assay kit which showed that
the splice variant had aggrecanase activity comparable to a commercially
available ADAMTS4. The puriﬁed splice variant was also found to cleave
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the Glu373-Ala374 aggrecanase site of aggrecan, as assessed by the neoepi-
tope monoclonal antibody BC3, and again this activity was comparable to
ADAMTS4.
Conclusions: ADAMTS4 is regulated at multiple levels through control of
gene expression, mRNA splicing and protein processing, as well as the
expression of naturally occurring inhibitors. Although alternative splicing
has been described in other ADAMTS family members, we here present the
ﬁrst known splice variant of ADAMTS4, occurring in human OA synovium,
but not in other human tissues tested, or in normal bovine synovium.
It is likely that the changes in the C-terminal domain of the protein
resulting from this alternatively spliced transcript would have changes in
its substrate speciﬁcity. The resulting protein has aggrecanase activity, and
it is possible that the release of low levels of this fully active variant of
ADAMTS4 might be a factor in the slow process of superﬁcial zone aggrecan
loss in osteoarthritis.
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MATRIPTASE IS A NOVEL INITIATOR OF CARTILAGE MATRIX RESORPTION
IN OSTEOARTHRITIS
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Purpose: Although matrix metalloproteinases (MMPs) are most strongly
associated with the proteolytic destruction of articular cartilage in os-
teoarthritis (OA), increasing data implicate serine proteinases in such
pathological tissue turnover. We have consistently shown that serine
proteinases interact with the MMPs in the cascades leading to cartilage
collagen resorption. Since collagenolysis is initiated around chondrocytes,
membranous serine proteinases may well contribute to disease. We
therefore screened OA cartilage for serine proteinases including the trans-
membrane serine proteinases (TTSPs) as candidate enzymes with a role in
tissue destruction.
Methods: Serine proteinase gene expression in femoral head cartilage from
either hip OA or fracture to the neck of femur (NOF) patients was assessed
using a custom Taqman low density array. The effect of matriptase on col-
lagen breakdown was determined in cartilage degradation models, whilst
the effect on MMP expression was analyzed by real-time PCR. Activation
of proMMPs was determined using SDS-PAGE and N-terminal sequencing.
Activation of proteinase-activated receptor-2 (PAR-2) was performed in a
synovial perfusion assay in mice.
Results: Matriptase gene expression is signiﬁcantly elevated in cartilage
from OA patients compared to NOF and matriptase is immunolocalized to
OA chondrocytes. We show matriptase can activate proMMP-1 and -3 to its
fully active form. Matriptase alone when added to OA cartilage in explant
culture causes signiﬁcant collagenolysis which is metalloproteinase-
dependent. Matriptase also induces MMP-1, -3 and -13 gene expression
in OA cartilage. Synovial perfusion data conﬁrmed matriptase to activate
